© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Latest Conference Articles
Rocatinlimab Shows Significant Efficacy in Moderate to Severe Atopic Dermatitis: Phase 3 IGNITE Trial Results
March 8th 2025
AAD 2025: The IGNITE study of the OX40 inhibitor included adults previously treated with a biologic or systemic JAK inhibitor, according to Amgen and Kyowa Kirin.
Icotrokinra Shows Promise for Moderate-to-Severe Plaque Psoriasis in Phase 3 Trials
March 8th 2025
Icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, which is implicated in multiple inflammatory conditions including plaque psoriasis.
Tapinarof Cream 1% Demonstrates Sustained Disease Control in Adults, Children with Atopic Dermatitis
March 8th 2025
AAD 2025: New analysis of the ADORING 3 trial showed tapinarof maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.
Lebrikizumab Improves Patient-Reported Outcomes in Atopic Dermatitis for Patients Previously Treated with Dupilumab
March 8th 2025
The proportion of participants with poor response to dupilumab who achieved a PNRS improvement of 3 points or greater was 72.9% at week 16 and 77.5% at week 24.
Ruxolitinib Cream Demonstrates Long-Term Disease Control in Atopic Dermatitis
March 7th 2025
By the end of the TRuE-AD1 and TRuE-AD 2 studies, 30.0% of participants met all 4 disease control criteria.
Real-World Evidence Reveals Key Insights on Hidradenitis Suppurativa
March 7th 2025
Two posters at AAD 2025 highlighted different challenges of managing patients with HS.
Bimekizumab Demonstrates Sustained Efficacy in Moderate-to-Severe Plaque Psoriasis Over Five Years
March 7th 2025
AAD 2025. New research indicates that dual inhibition of IL-17A and IL-17F with bimekizumab maintains high rates of complete skin clearance for up to 5 years.
Roflumilast Foam 0.3% Significantly Reduces Pruritus and Improves Quality of Life in Scalp and Body Psoriasis
March 7th 2025
More than half (55.4%) of roflumilast-treated patients achieved a score of 0 or 1 vs 19.8% in the vehicle group on the Worst Itch-NRS numeric rating scale.
Roflumilast Cream 0.15% Well Tolerated in Atopic Dermatitis Patients with Prior Treatment Failures
March 7th 2025
Participants in the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials had failed treatment with topical corticosteroids and calcineurin inhibitors or crisaborole.
Tildrakizumab Shows Efficacy for Nail Psoriasis in Phase 3b Trial
March 7th 2025
The findings highlight the potential of the interleukin-23 inhibitor to address a notoriously difficult-to-treat manifestation of psoriasis.